Cellectar Biosciences Inc (NAS:CLRB)
$ 2.501 +0.030 (+1.2%) Market Cap: 19.99 Mil Enterprise Value: 13.84 Mil PE Ratio: 0 PB Ratio: 3.82 GF Score: 28/100

Q4 2025 Cellectar Biosciences Inc Earnings Call Transcript

Mar 04, 2026 / 01:30PM GMT
Release Date Price: $2.9 (+8.21%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome. (Operator Instructions) Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Ann Marie Fields, Managing Director at Precision AQ. Please go ahead.

Anne Marie Fields
Precision AQ - Investor Relations

Thank you, operator. Good morning, and welcome to Cellectar Biosciences Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call. Joining us today from Cellectar are Jim Caruso, President and CEO, who will provide an overview of the company's progress before turning the call over to Chad Kolean, CFO, for a financial review of the quarter and the year. Following this, Jarrod Longcor, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical development pipeline of radiopharmaceuticals.

Cellectar issued release earlier this morning detailing the content of today's call. A copy can be found on the Investor page of Cellectar's corporate website. I want to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot